Alvin Shih
Director/Board Member bei ZEVRA THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Alvin Shih is currently the President, Chief Executive Officer & Director at Catamaran Bio, Inc. He is also an Independent Director at Zevra Therapeutics, Inc. and a Director at Rare-X.
Previously, he served as the President, Chief Executive Officer & Director at Disarm Therapeutics, Inc. from 2019 to 2020.
He was the Chief Executive Officer at Enzyvant, Inc. from 2016 to 2019.
Prior to that, he held the position of Executive Vice President-Research & Development at Travere Therapeutics, Inc. from 2014 to 2016.
He also served as the chief operating officer at Pfizer Inc. from 2010 to 2014.
Additionally, he was an Executive Vice President & Head-Research at Retrophin, Inc. Dr. Shih completed his undergraduate degree at Vanderbilt University.
He holds an MBA from Kellogg School of Management.
He also obtained a doctorate degree from The University of Alabama School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
-.--% | 22.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Alvin Shih
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Director/Board Member | 20.01.2024 |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Chief Executive Officer | 04.02.2021 |
Rare-X
 Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Director/Board Member | - |
Ehemalige bekannte Positionen von Alvin Shih
| Unternehmen | Position | Ende |
|---|---|---|
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.10.2020 |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Chief Executive Officer | 21.02.2019 |
| TRAVERE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31.10.2016 |
| PFIZER, INC. | Chief Operating Officer | 01.05.2014 |
Ausbildung von Alvin Shih
| Vanderbilt University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
| The University of Alabama School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Technology Services |
